Escalate: Linezolid as an add on treatment in the intensive phase of tubercular meningitis - a randomized controlled trial

Abstract

TBM has the highest morbidity and mortality, chiefly in the initial few days to weeks and therefore it is important to modify the principles of the treatment to prevent this. AIMS To observe if administration of Linezolid along with four drug standard weight ATT based regimen in intensive phase of treatment in TBM will be safe and help reduce mortality and morbidity at 1 and 3 months among patients with TBM when compared to standard ATT alone.